Treatment of Heart Failure with ACE Inhibitors and Beta-blockers: What is Next? AT1-receptor Antagonists?

Overview

Journal Clin Res Cardiol

Specialty Cardiology & Vascular Diseases

Date 2007 Feb 13

PMID 17294351

Citations 10

Authors

Uta C Hoppe

Affiliations

Soon will be listed here.

Citing Articles

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Martin N, Manoharan K, Davies C, Lumbers R Cochrane Database Syst Rev. 2021; 5:CD012721.

PMID: 34022072 PMC: 8140651. DOI: 10.1002/14651858.CD012721.pub3.

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Martin N, Manoharan K, Thomas J, Davies C, Lumbers R Cochrane Database Syst Rev. 2018; 6:CD012721.

PMID: 29952095 PMC: 6513293. DOI: 10.1002/14651858.CD012721.pub2.

ACE inhibitors - angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease.

Saleem T, Bharani K, Gauthaman K Open Access Emerg Med. 2016; 2:51-9.

PMID: 27147838 PMC: 4806827. DOI: 10.2147/oaem.s10507.

Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?.

Werner C, Poss J, Bohm M Drugs. 2010; 70(10):1215-30.

PMID: 20568830 DOI: 10.2165/11537910-000000000-00000.

Individuals at risk of beta-blocker discontinuation: a cohort study in 19,177 Chinese patients.

Wong M, Jiang J, Su X, Wang H, Tang J, Griffiths S Clin Res Cardiol. 2010; 99(5):277-84.

PMID: 20174812 DOI: 10.1007/s00392-010-0114-1.

References

Biollaz J, Brunner H, Gavras I, Waeber B, Gavras H . Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982; 4(6):966-72. View

van de Wal R, Plokker H, Lok D, Boomsma F, van der Horst F, van Veldhuisen D . Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol. 2005; 106(3):367-72. DOI: 10.1016/j.ijcard.2005.02.016. View

Pfeffer M, McMurray J, Velazquez E, Rouleau J, Kober L, Maggioni A . Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349(20):1893-906. DOI: 10.1056/NEJMoa032292. View

Voors A, van Veldhuisen D . Role of angiotensin receptor blockers in patients with left ventricular dysfunction: lessons from CHARM and VALIANT. Int J Cardiol. 2004; 97(3):345-8. DOI: 10.1016/j.ijcard.2004.03.062. View

Linz W, Wiemer G, Gohlke P, Unger T, Scholkens B . Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995; 47(1):25-49. View

Azizi M, Menard J . Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004; 109(21):2492-9. DOI: 10.1161/01.CIR.0000131449.94713.AD. View

Iyer S, Chappell M, Averill D, Diz D, Ferrario C . Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension. 1998; 31(2):699-705. DOI: 10.1161/01.hyp.31.2.699. View

van de Wal R, Van Veldhuisen D, van Gilst W, Voors A . Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?. Eur Heart J. 2005; 26(22):2361-7. DOI: 10.1093/eurheartj/ehi454. View

Okunishi H, Miyazaki M, Toda N . Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens. 1984; 2(3):277-84. View

10.

Urata H, Kinoshita A, Misono K, BUMPUS F, Husain A . Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990; 265(36):22348-57. View

11.

Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Waeber B . Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990; 16(5):564-72. DOI: 10.1161/01.hyp.16.5.564. View

12.

McMurray J, Ostergren J, Swedberg K, Granger C, Held P, Michelson E . Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003; 362(9386):767-71. DOI: 10.1016/S0140-6736(03)14283-3. View

13.

Krum H, Carson P, Farsang C, Maggioni A, Glazer R, Aknay N . Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail. 2004; 6(7):937-45. DOI: 10.1016/j.ejheart.2004.09.005. View

14.

Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M . Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 1999; 21(1):53-7. DOI: 10.1053/euhj.1999.1740. View

15.

Azizi M, Rousseau A, Ezan E, Guyene T, Michelet S, Grognet J . Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest. 1996; 97(3):839-44. PMC: 507123. DOI: 10.1172/JCI118484. View

16.

Cohn J, Tognoni G . A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2002; 345(23):1667-75. DOI: 10.1056/NEJMoa010713. View

17.

Jorde U, Ennezat P, Lisker J, Suryadevara V, Infeld J, Cukon S . Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation. 2000; 101(8):844-6. DOI: 10.1161/01.cir.101.8.844. View

18.

Hunt S, Abraham W, Chin M, Feldman A, Francis G, Ganiats T . ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001.... Circulation. 2005; 112(12):e154-235. DOI: 10.1161/CIRCULATIONAHA.105.167586. View

19.

Carey R, Wang Z, Siragy H . Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension. 2000; 35(1 Pt 2):155-63. DOI: 10.1161/01.hyp.35.1.155. View